[
  {
    "ts": "2025-11-03T23:17:00+00:00",
    "headline": "Does the Market Have Bad Breadth?",
    "summary": "Is the breadth in this market, or lack thereof, a sign of weakening trading sentiment?",
    "url": "https://finance.yahoo.com/news/does-market-bad-breadth-231700684.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "89b8df19-600d-30ed-950e-b621fca9d8d8",
      "content": {
        "id": "89b8df19-600d-30ed-950e-b621fca9d8d8",
        "contentType": "STORY",
        "title": "Does the Market Have Bad Breadth?",
        "description": "",
        "summary": "Is the breadth in this market, or lack thereof, a sign of weakening trading sentiment?",
        "pubDate": "2025-11-03T23:17:00Z",
        "displayTime": "2025-11-03T23:17:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/does-market-bad-breadth-231700684.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/does-market-bad-breadth-231700684.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "BP"
            },
            {
              "symbol": "BPAQF"
            },
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "UBER"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "CLX"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T22:07:35+00:00",
    "headline": "Nasdaq, S&P 500 Rise in Mixed Session as Amazon Leads Tech Advance",
    "summary": "The Nasdaq Composite and the S&P 500 advanced in an overall mixed session on Monday, with Amazon.com",
    "url": "https://finance.yahoo.com/news/nasdaq-p-500-rise-mixed-220735028.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "dcd3fba4-68cb-3e15-b3cb-103d35626415",
      "content": {
        "id": "dcd3fba4-68cb-3e15-b3cb-103d35626415",
        "contentType": "STORY",
        "title": "Nasdaq, S&P 500 Rise in Mixed Session as Amazon Leads Tech Advance",
        "description": "",
        "summary": "The Nasdaq Composite and the S&P 500 advanced in an overall mixed session on Monday, with Amazon.com",
        "pubDate": "2025-11-03T22:07:35Z",
        "displayTime": "2025-11-03T22:07:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/mt_newswires_premium_news_706/2475a8618428bf41d7b045240805a142",
          "originalWidth": 1000,
          "originalHeight": 750,
          "caption": "stocks market trading wall street equity  - Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R1yQsOWM_4gTNykv.hQBwA--~B/aD03NTA7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mt_newswires_premium_news_706/2475a8618428bf41d7b045240805a142.cf.webp",
              "width": 1000,
              "height": 750,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/diSe6bGT1d66Fb2vv7Kgwg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/mt_newswires_premium_news_706/2475a8618428bf41d7b045240805a142.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nasdaq-p-500-rise-mixed-220735028.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nasdaq-p-500-rise-mixed-220735028.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "OPAI.PVT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T21:26:29+00:00",
    "headline": "Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo",
    "summary": "Metsera called Pfizer's claims \"nonsense\" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.",
    "url": "https://www.investors.com/news/technology/metsera-pfizer-novo-nordisk-takeover-litigation/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "2a29075c-3725-3bda-bb69-b3d77841b07b",
      "content": {
        "id": "2a29075c-3725-3bda-bb69-b3d77841b07b",
        "contentType": "STORY",
        "title": "Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo",
        "description": "",
        "summary": "Metsera called Pfizer's claims \"nonsense\" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.",
        "pubDate": "2025-11-03T21:26:29Z",
        "displayTime": "2025-11-03T21:26:29Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/2a29075c-3725-3bda-bb69-b3d77841b07b/metsera-calls-pfizer-s-claims.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/3dffc435f585895e4f9c02c947878503",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JiB.MKe4.kKoFP7tJVVVFA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/3dffc435f585895e4f9c02c947878503.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ReA03i3fOiLRtVTA7uA7gg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/3dffc435f585895e4f9c02c947878503.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/metsera-pfizer-novo-nordisk-takeover-litigation/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T21:11:00+00:00",
    "headline": "Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer.",
    "summary": "The 11th-hour attempt by Novo to snatch away Metsera, which Pfizer had agreed to buy in September, has upended debate around the company.",
    "url": "https://www.barrons.com/articles/pfizer-earnings-stock-price-b3e0f846?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "7246ffe5-2485-388a-8752-9173aaedd1a6",
      "content": {
        "id": "7246ffe5-2485-388a-8752-9173aaedd1a6",
        "contentType": "STORY",
        "title": "Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer.",
        "description": "",
        "summary": "The 11th-hour attempt by Novo to snatch away Metsera, which Pfizer had agreed to buy in September, has upended debate around the company.",
        "pubDate": "2025-11-03T21:11:00Z",
        "displayTime": "2025-11-03T21:11:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/7246ffe5-2485-388a-8752-9173aaedd1a6/pfizer-reports-earnings.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/e79eb7dfaf2e2d22b9f8fc4c7613425c",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8PiGpf4wc.D72W144T1Axw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/e79eb7dfaf2e2d22b9f8fc4c7613425c.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q89MYulGiIu1k2xQkauN0g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/e79eb7dfaf2e2d22b9f8fc4c7613425c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/pfizer-earnings-stock-price-b3e0f846?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T19:09:00+00:00",
    "headline": "Equities Mostly Rise Intraday Amid Amazon Boost as Markets Await Week's Key Earnings",
    "summary": "US benchmark equity indexes were mostly higher after midday Monday amid a jump in Amazon.com (AMZN)",
    "url": "https://finance.yahoo.com/news/equities-mostly-rise-intraday-amid-190900249.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "d9e61d10-7cf8-314e-98ef-ed442425de16",
      "content": {
        "id": "d9e61d10-7cf8-314e-98ef-ed442425de16",
        "contentType": "STORY",
        "title": "Equities Mostly Rise Intraday Amid Amazon Boost as Markets Await Week's Key Earnings",
        "description": "",
        "summary": "US benchmark equity indexes were mostly higher after midday Monday amid a jump in Amazon.com (AMZN)",
        "pubDate": "2025-11-03T19:09:00Z",
        "displayTime": "2025-11-03T19:09:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/mt_newswires_premium_news_706/0c887a492733aab96ac405a5871f559a",
          "originalWidth": 1024,
          "originalHeight": 768,
          "caption": "Stocks_Chart market equity trading wall street - Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0eWqzzTTIs4ZCQG0VOzLjA--~B/aD03Njg7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mt_newswires_premium_news_706/0c887a492733aab96ac405a5871f559a.cf.webp",
              "width": 1024,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/woUn3cfJYPXMhxA4_4CCeg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/mt_newswires_premium_news_706/0c887a492733aab96ac405a5871f559a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/equities-mostly-rise-intraday-amid-190900249.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/equities-mostly-rise-intraday-amid-190900249.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "OPAI.PVT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T18:59:33+00:00",
    "headline": "Sector Update: Health Care Stocks Decline in Afternoon Trading",
    "summary": "Health care stocks declined Monday afternoon, with the NYSE Health Care Index shedding 0.3% and the",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-decline-185933535.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "cda87691-0f94-39df-ba5d-d0affa2bdfad",
      "content": {
        "id": "cda87691-0f94-39df-ba5d-d0affa2bdfad",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Decline in Afternoon Trading",
        "description": "",
        "summary": "Health care stocks declined Monday afternoon, with the NYSE Health Care Index shedding 0.3% and the",
        "pubDate": "2025-11-03T18:59:33Z",
        "displayTime": "2025-11-03T18:59:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-decline-185933535.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-decline-185933535.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "AUPH"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T18:23:00+00:00",
    "headline": "Did Novo Nordisk Just Say \"Checkmate\" to Pfizer?",
    "summary": "These two leading drugmakers are fighting over a promising GLP-1 candidate.",
    "url": "https://www.fool.com/investing/2025/11/03/did-novo-nordisk-just-say-checkmate-to-pfizer/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "f64fb8c4-929e-392d-926a-83f1ee05c18a",
      "content": {
        "id": "f64fb8c4-929e-392d-926a-83f1ee05c18a",
        "contentType": "STORY",
        "title": "Did Novo Nordisk Just Say \"Checkmate\" to Pfizer?",
        "description": "",
        "summary": "These two leading drugmakers are fighting over a promising GLP-1 candidate.",
        "pubDate": "2025-11-03T18:23:00Z",
        "displayTime": "2025-11-03T18:23:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/d8e23dfa94216b26aaed3671969ecab6",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "Patient self-administering an injector pen.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xErl8F_ztVoSMJQxiwXM_Q--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/d8e23dfa94216b26aaed3671969ecab6.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NERE98UHG6fU4T2Xz9r3fw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/d8e23dfa94216b26aaed3671969ecab6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/03/did-novo-nordisk-just-say-checkmate-to-pfizer/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/did-novo-nordisk-just-checkmate-182300115.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T17:15:01+00:00",
    "headline": "Pfizer files second lawsuit to block Novo Nordisk’s $9bn Metsera bid",
    "summary": "Pfizer has filed a second lawsuit against Novo Nordisk and obesity drug start-up Metsera, redoubling its fight to stop Novo’s bid for the biotech...",
    "url": "https://finance.yahoo.com/news/pfizer-files-second-lawsuit-block-140426446.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "6686d460-781f-3b36-a39c-7e801ab60e92",
      "content": {
        "id": "6686d460-781f-3b36-a39c-7e801ab60e92",
        "contentType": "STORY",
        "title": "Pfizer files second lawsuit to block Novo Nordisk’s $9bn Metsera bid",
        "description": "",
        "summary": "Pfizer has filed a second lawsuit against Novo Nordisk and obesity drug start-up Metsera, redoubling its fight to stop Novo’s bid for the biotech...",
        "pubDate": "2025-11-03T17:15:01Z",
        "displayTime": "2025-11-03T17:15:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-files-second-lawsuit-block-140426446.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-files-second-lawsuit-block-140426446.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T17:04:00+00:00",
    "headline": "Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera",
    "summary": "The lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by killing off a smaller competitor.",
    "url": "https://www.wsj.com/health/pharma/pfizer-files-antitrust-suit-to-block-novo-nordisk-acquisition-of-metsera-378823de?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "2ab550e5-4350-3d48-bd60-336ac3904445",
      "content": {
        "id": "2ab550e5-4350-3d48-bd60-336ac3904445",
        "contentType": "STORY",
        "title": "Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera",
        "description": "",
        "summary": "The lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by killing off a smaller competitor.",
        "pubDate": "2025-11-03T17:04:00Z",
        "displayTime": "2025-11-03T17:04:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/2ab550e5-4350-3d48-bd60-336ac3904445/pfizer-files-antitrust-suit.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/abf7a5f154b4cc6d5a969410412b9b8d",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PwW3_qC7cB2NTiEgt7jCIw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/abf7a5f154b4cc6d5a969410412b9b8d.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EE5apNZpI.TXjErrpBIjqw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/abf7a5f154b4cc6d5a969410412b9b8d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/pfizer-files-antitrust-suit-to-block-novo-nordisk-acquisition-of-metsera-378823de?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T17:03:00+00:00",
    "headline": "Pfizer Aligns With Trump on Drug Pricing In Its Bid for Biotech Metsera",
    "summary": "Pfizer has now filed a suit in federal court, following its claim in state court on Friday. It is riding Trump-era political currents in its efforts to save the deal.",
    "url": "https://www.barrons.com/articles/pfizer-trump-drug-prices-novo-nordisk-metsera-0abe8d51?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "cbb104d7-5c93-38e8-8b8a-8075677f9be1",
      "content": {
        "id": "cbb104d7-5c93-38e8-8b8a-8075677f9be1",
        "contentType": "STORY",
        "title": "Pfizer Aligns With Trump on Drug Pricing In Its Bid for Biotech Metsera",
        "description": "",
        "summary": "Pfizer has now filed a suit in federal court, following its claim in state court on Friday. It is riding Trump-era political currents in its efforts to save the deal.",
        "pubDate": "2025-11-03T17:03:00Z",
        "displayTime": "2025-11-03T17:03:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cbb104d7-5c93-38e8-8b8a-8075677f9be1/pfizer-aligns-with-trump-on.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/b316512601d6a4a77b9ba30bbac9d200",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fIURyh_GAbgwB5BDIn7bIw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/b316512601d6a4a77b9ba30bbac9d200.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/koZJpcM0YDLZkkieBHgKdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/b316512601d6a4a77b9ba30bbac9d200.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/pfizer-trump-drug-prices-novo-nordisk-metsera-0abe8d51?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T16:13:20+00:00",
    "headline": "Viking Therapeutics Could Be Pharma’s Next Big Buyout Target",
    "summary": "The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at over $100 billion today, the sector is projected to exceed $150 billion by 2030 as more patients seek effective therapies. Viking Therapeutics (NASDAQ:VKTX) is ... Viking Therapeutics Could Be Pharma’s Next Big Buyout Target",
    "url": "https://247wallst.com/investing/2025/11/03/viking-therapeutics-could-be-pharmas-next-big-buyout-target/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "3e2eb745-2faa-36d9-ac93-8e34c532bb74",
      "content": {
        "id": "3e2eb745-2faa-36d9-ac93-8e34c532bb74",
        "contentType": "STORY",
        "title": "Viking Therapeutics Could Be Pharma’s Next Big Buyout Target",
        "description": "",
        "summary": "The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at over $100 billion today, the sector is projected to exceed $150 billion by 2030 as more patients seek effective therapies. Viking Therapeutics (NASDAQ:VKTX) is ... Viking Therapeutics Could Be Pharma’s Next Big Buyout Target",
        "pubDate": "2025-11-03T16:13:20Z",
        "displayTime": "2025-11-03T16:13:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/6464e26647b487fe91e406f103aa3998",
          "originalWidth": 1366,
          "originalHeight": 767,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/euS9UOm2knyrB0G7VM9FLw--~B/aD03Njc7dz0xMzY2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/6464e26647b487fe91e406f103aa3998.cf.webp",
              "width": 1366,
              "height": 767,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9GqBZFX6mIftCTG_Z_9hDw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/6464e26647b487fe91e406f103aa3998.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2025/11/03/viking-therapeutics-could-be-pharmas-next-big-buyout-target/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viking-therapeutics-could-pharma-next-161320501.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T16:06:41+00:00",
    "headline": "Jim Cramer on Pfizer: “We’ll Find Out if Pfizer’s Going to Be More of a Stock and Less of a Bond Equivalent”",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer had in this week’s game plan. Cramer discussed the future possibilities of the stock, as he commented: “Now, will Pfizer break out from the $25 level? Oh, it’s been a dull run for this former growth drug stock as shareholders seem to be satisfied with […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-pfizer-ll-pfizer-160641480.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "50ee9472-7f1d-3ae8-ae4a-f9ab45d59d6a",
      "content": {
        "id": "50ee9472-7f1d-3ae8-ae4a-f9ab45d59d6a",
        "contentType": "STORY",
        "title": "Jim Cramer on Pfizer: “We’ll Find Out if Pfizer’s Going to Be More of a Stock and Less of a Bond Equivalent”",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer had in this week’s game plan. Cramer discussed the future possibilities of the stock, as he commented: “Now, will Pfizer break out from the $25 level? Oh, it’s been a dull run for this former growth drug stock as shareholders seem to be satisfied with […]",
        "pubDate": "2025-11-03T16:06:41Z",
        "displayTime": "2025-11-03T16:06:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/bede06ab4149315d5115f133c0b1480c",
          "originalWidth": 1920,
          "originalHeight": 1272,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lBNvOkwEcDTC6JSi8u6u5Q--~B/aD0xMjcyO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/bede06ab4149315d5115f133c0b1480c.cf.webp",
              "width": 1920,
              "height": 1272,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l4R272WQ4gg_U7DbC5QzrA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bede06ab4149315d5115f133c0b1480c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-pfizer-ll-pfizer-160641480.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-pfizer-ll-pfizer-160641480.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T16:02:00+00:00",
    "headline": "Metsera Issues Statement in Response to Litigation",
    "summary": "Metsera, Inc. (NASDAQ: MTSR) (\"Metsera\" or the \"Company\") today issued the following statement in response to litigation filed against the Company by Pfizer:",
    "url": "https://finance.yahoo.com/news/metsera-issues-statement-response-litigation-160200573.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "39f164cf-64d5-3ecb-8410-b89c3b0df0f7",
      "content": {
        "id": "39f164cf-64d5-3ecb-8410-b89c3b0df0f7",
        "contentType": "STORY",
        "title": "Metsera Issues Statement in Response to Litigation",
        "description": "",
        "summary": "Metsera, Inc. (NASDAQ: MTSR) (\"Metsera\" or the \"Company\") today issued the following statement in response to litigation filed against the Company by Pfizer:",
        "pubDate": "2025-11-03T16:02:00Z",
        "displayTime": "2025-11-03T16:02:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/65060960b337067e31dd837f7e51bbed",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2fm9tgNRx7_evqueiA_OEg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/65060960b337067e31dd837f7e51bbed.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Z8NseBWmy1lHQCP4UeVBUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/65060960b337067e31dd837f7e51bbed.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/metsera-issues-statement-response-litigation-160200573.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/metsera-issues-statement-response-litigation-160200573.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T15:15:00+00:00",
    "headline": "Update: Pfizer Sues Metsera, Novo Nordisk Over Alleged Breach of Merger Agreement",
    "summary": "(Updates to add comment from Novo Nordisk in the sixth paragraph.) Pfizer (PFE) said late Friday",
    "url": "https://finance.yahoo.com/news/pfizer-sues-metsera-novo-nordisk-151500673.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "10a3f383-9b81-3ffc-8256-449b91896a9a",
      "content": {
        "id": "10a3f383-9b81-3ffc-8256-449b91896a9a",
        "contentType": "STORY",
        "title": "Update: Pfizer Sues Metsera, Novo Nordisk Over Alleged Breach of Merger Agreement",
        "description": "",
        "summary": "(Updates to add comment from Novo Nordisk in the sixth paragraph.) Pfizer (PFE) said late Friday",
        "pubDate": "2025-11-03T15:15:00Z",
        "displayTime": "2025-11-03T15:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-sues-metsera-novo-nordisk-151500673.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-sues-metsera-novo-nordisk-151500673.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T12:57:00+00:00",
    "headline": "Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk",
    "summary": "NEW YORK, November 03, 2025--Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware.",
    "url": "https://finance.yahoo.com/news/pfizer-files-federal-antitrust-claims-125700998.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "b6f17320-69d2-3828-8c8b-e2b030b1ea68",
      "content": {
        "id": "b6f17320-69d2-3828-8c8b-e2b030b1ea68",
        "contentType": "STORY",
        "title": "Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk",
        "description": "",
        "summary": "NEW YORK, November 03, 2025--Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware.",
        "pubDate": "2025-11-03T12:57:00Z",
        "displayTime": "2025-11-03T12:57:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/48473e01d7a9e1ca1ad824d2e298dfe6",
          "originalWidth": 480,
          "originalHeight": 212,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/THWUIzrGBxEQK61woHCNTw--~B/aD0yMTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/48473e01d7a9e1ca1ad824d2e298dfe6.cf.webp",
              "width": 480,
              "height": 212,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/226JIKngiMQbZAv2vv9w2A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/48473e01d7a9e1ca1ad824d2e298dfe6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-files-federal-antitrust-claims-125700998.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-files-federal-antitrust-claims-125700998.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T12:44:43+00:00",
    "headline": "Pfizer hits Novo Nordisk and Metsera with lawsuit amid bidding war",
    "summary": "Pfizer called Novo Nordisk’s last-minute bid to acquire Metsera “reckless and unprecedented”.",
    "url": "https://www.pharmaceutical-technology.com/news/pfizer-novo-nordisk-metsera-acquisition-lawsuit/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "f2c19d89-4a41-3fe1-9f36-4d4f5ae389f3",
      "content": {
        "id": "f2c19d89-4a41-3fe1-9f36-4d4f5ae389f3",
        "contentType": "STORY",
        "title": "Pfizer hits Novo Nordisk and Metsera with lawsuit amid bidding war",
        "description": "",
        "summary": "Pfizer called Novo Nordisk’s last-minute bid to acquire Metsera “reckless and unprecedented”.",
        "pubDate": "2025-11-03T12:44:43Z",
        "displayTime": "2025-11-03T12:44:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/c3cd8e13b00e45f9f02d2775ba9fa4b3",
          "originalWidth": 1000,
          "originalHeight": 562,
          "caption": "Pfizer has filed a lawsuit against rival big pharma company",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F_MWKHxxH.3jscyfi2203w--~B/aD01NjI7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/c3cd8e13b00e45f9f02d2775ba9fa4b3.cf.webp",
              "width": 1000,
              "height": 562,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_rDzIaKGNM__qzwQUSPmTA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/c3cd8e13b00e45f9f02d2775ba9fa4b3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/pfizer-novo-nordisk-metsera-acquisition-lawsuit/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-hits-novo-nordisk-metsera-124443084.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T12:37:00+00:00",
    "headline": "2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon",
    "summary": "These healthcare stocks are making strides in very important ways.",
    "url": "https://www.fool.com/investing/2025/11/03/2-healthcare-stocks-for-investors-with-a-20-year/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "8f04277a-7116-3e76-9aed-588f39f7e5fa",
      "content": {
        "id": "8f04277a-7116-3e76-9aed-588f39f7e5fa",
        "contentType": "STORY",
        "title": "2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon",
        "description": "",
        "summary": "These healthcare stocks are making strides in very important ways.",
        "pubDate": "2025-11-03T12:37:00Z",
        "displayTime": "2025-11-03T12:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/d38fcef9326aeb895f925247ddffedce",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A smiling person wearing a burgundy suit and glasses stands against a blue wall.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0vCKOHUfGfj11BU3umqTHw--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/d38fcef9326aeb895f925247ddffedce.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_BCV9H_kryQlDtESZCbQuA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/d38fcef9326aeb895f925247ddffedce.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/03/2-healthcare-stocks-for-investors-with-a-20-year/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-healthcare-stocks-individual-investors-123700266.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T12:34:01+00:00",
    "headline": "Stocks Gain Pre-Bell as Traders Eye Strong Start to November, Await More Earnings",
    "summary": "The benchmark US stock measures were tracking in the green before the opening bell Monday as traders",
    "url": "https://finance.yahoo.com/news/stocks-gain-pre-bell-traders-123401495.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "d9d6a4bd-97db-3341-989b-8b79ddc38bf6",
      "content": {
        "id": "d9d6a4bd-97db-3341-989b-8b79ddc38bf6",
        "contentType": "STORY",
        "title": "Stocks Gain Pre-Bell as Traders Eye Strong Start to November, Await More Earnings",
        "description": "",
        "summary": "The benchmark US stock measures were tracking in the green before the opening bell Monday as traders",
        "pubDate": "2025-11-03T12:34:01Z",
        "displayTime": "2025-11-03T12:34:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/mt_newswires_premium_news_706/8685121785649cec3dbcdbbd25333a86",
          "originalWidth": 1024,
          "originalHeight": 683,
          "caption": "wall street stock market flag new york trading equity - Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QVMgErJdOR7IkzCjRHm3pQ--~B/aD02ODM7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mt_newswires_premium_news_706/8685121785649cec3dbcdbbd25333a86.cf.webp",
              "width": 1024,
              "height": 683,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dimQxOClk1isv1IKNf9JtA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/mt_newswires_premium_news_706/8685121785649cec3dbcdbbd25333a86.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/stocks-gain-pre-bell-traders-123401495.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stocks-gain-pre-bell-traders-123401495.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "NVDA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T11:12:34+00:00",
    "headline": "Pfizer Sues Metsera, Novo Nordisk Over Alleged Breach of Merger Agreement",
    "summary": "Pfizer (PFE) said late Friday it filed a lawsuit against Metsera (MTSR), its board of directors, and",
    "url": "https://finance.yahoo.com/news/pfizer-sues-metsera-novo-nordisk-111234102.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "6392bf4a-29b4-3048-9914-c292a201f5b0",
      "content": {
        "id": "6392bf4a-29b4-3048-9914-c292a201f5b0",
        "contentType": "STORY",
        "title": "Pfizer Sues Metsera, Novo Nordisk Over Alleged Breach of Merger Agreement",
        "description": "",
        "summary": "Pfizer (PFE) said late Friday it filed a lawsuit against Metsera (MTSR), its board of directors, and",
        "pubDate": "2025-11-03T11:12:34Z",
        "displayTime": "2025-11-03T11:12:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-sues-metsera-novo-nordisk-111234102.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-sues-metsera-novo-nordisk-111234102.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T11:06:00+00:00",
    "headline": "Lung Cancer Antibody Drug Conjugates Research 2025: A $2 Billion Opportunity in 2030, Led by AstraZeneca, Daiichi Sankyo, Pfizer, and BMS Advancing Targeted Therapies Against HER2, TROP-2, and B7-H3",
    "summary": "Opportunities in the lung cancer antibody drug conjugates market include developing specific, low-toxicity therapies using ADCs, capitalizing on technology platforms like DXd, leveraging collaboration among major firms, and exploring personalized and combination therapies targeting specific genetic mutations and tumor antigens.Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The \"Lung Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price & Clinical Trials Insight 2030\" report has been added",
    "url": "https://finance.yahoo.com/news/lung-cancer-antibody-drug-conjugates-110600020.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "3f6e0b8c-3a18-31c6-afde-dc24c62b84c1",
      "content": {
        "id": "3f6e0b8c-3a18-31c6-afde-dc24c62b84c1",
        "contentType": "STORY",
        "title": "Lung Cancer Antibody Drug Conjugates Research 2025: A $2 Billion Opportunity in 2030, Led by AstraZeneca, Daiichi Sankyo, Pfizer, and BMS Advancing Targeted Therapies Against HER2, TROP-2, and B7-H3",
        "description": "",
        "summary": "Opportunities in the lung cancer antibody drug conjugates market include developing specific, low-toxicity therapies using ADCs, capitalizing on technology platforms like DXd, leveraging collaboration among major firms, and exploring personalized and combination therapies targeting specific genetic mutations and tumor antigens.Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The \"Lung Cancer Antibody Drug Conjugates Market Opportunity, Patent, Price & Clinical Trials Insight 2030\" report has been added",
        "pubDate": "2025-11-03T11:06:00Z",
        "displayTime": "2025-11-03T11:06:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lung-cancer-antibody-drug-conjugates-110600020.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lung-cancer-antibody-drug-conjugates-110600020.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "4568.T"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN.L"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T10:22:26+00:00",
    "headline": "ESMO 2025: Celcuity gets first positive results for Pi3K inhibitor in PiK3CA wild-type HR+/HER2 breast cancer",
    "summary": "The design of the Phase 3 clinical trial and the agent’s profile position Celcuity well.",
    "url": "https://www.clinicaltrialsarena.com/analyst-comment/esmo-2025-celcuity-positive-results-pi3k-inhibitor-breast-cancer/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "4ad84fa2-5bc4-3001-91f0-c8bd6af71f11",
      "content": {
        "id": "4ad84fa2-5bc4-3001-91f0-c8bd6af71f11",
        "contentType": "STORY",
        "title": "ESMO 2025: Celcuity gets first positive results for Pi3K inhibitor in PiK3CA wild-type HR+/HER2 breast cancer",
        "description": "",
        "summary": "The design of the Phase 3 clinical trial and the agent’s profile position Celcuity well.",
        "pubDate": "2025-11-03T10:22:26Z",
        "displayTime": "2025-11-03T10:22:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/ddd02f853fbe709f743e58fe3274994f",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "GlobalData’s analyst consensus forecast for gedatolisib is set to generate $827m in 2031. Credit: Jo Panuwat D/Shutterstock.com.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1HHHKz2._egOoUh0RgpHPQ--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/ddd02f853fbe709f743e58fe3274994f.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/He9u38N4kTsMswScd2OqHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/ddd02f853fbe709f743e58fe3274994f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/analyst-comment/esmo-2025-celcuity-positive-results-pi3k-inhibitor-breast-cancer/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/esmo-2025-celcuity-gets-first-102226442.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELC"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T10:12:00+00:00",
    "headline": "United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb",
    "summary": "Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The \"United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and",
    "url": "https://finance.yahoo.com/news/united-states-multiple-myeloma-market-101200827.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "3d33767a-80a0-39f6-b425-cf0864c74745",
      "content": {
        "id": "3d33767a-80a0-39f6-b425-cf0864c74745",
        "contentType": "STORY",
        "title": "United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb",
        "description": "",
        "summary": "Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The \"United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and",
        "pubDate": "2025-11-03T10:12:00Z",
        "displayTime": "2025-11-03T10:12:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/f0ad8df6a5e435cb735622670df8b993",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "U.S. Multiple Myeloma Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wCmcQt.cLkDgg20dBnjnRg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f0ad8df6a5e435cb735622670df8b993.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/q92hRNIoyDOn3lP6EHRHpw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f0ad8df6a5e435cb735622670df8b993.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/united-states-multiple-myeloma-market-101200827.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/united-states-multiple-myeloma-market-101200827.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "SAN.PA"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BAX"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "4502.T"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T09:46:00+00:00",
    "headline": "Meet the 7% Yield Dividend Stock That Could Soar in 2026",
    "summary": "This out-of-favor drug maker is taking the steps needed to ensure it not only survives but thrives over the long term.",
    "url": "https://www.fool.com/investing/2025/11/03/7-percent-yield-dividend-stock-could-soar-in-2026/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "7d24370a-b7c2-349e-b010-a2cc1198faff",
      "content": {
        "id": "7d24370a-b7c2-349e-b010-a2cc1198faff",
        "contentType": "STORY",
        "title": "Meet the 7% Yield Dividend Stock That Could Soar in 2026",
        "description": "",
        "summary": "This out-of-favor drug maker is taking the steps needed to ensure it not only survives but thrives over the long term.",
        "pubDate": "2025-11-03T09:46:00Z",
        "displayTime": "2025-11-03T09:46:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/7e10778d44d6abc0605c4e68c43c25b4",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "A person standing with a U-turn symbol on the ground in from of them.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rZum07iv4_x1w4C65WjFBA--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/7e10778d44d6abc0605c4e68c43c25b4.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d0naXtJZoC.kzZB4DR.mAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/7e10778d44d6abc0605c4e68c43c25b4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/03/7-percent-yield-dividend-stock-could-soar-in-2026/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/meet-7-yield-dividend-stock-094600716.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T09:00:00+00:00",
    "headline": "1 Incredible Reason to Buy Pfizer Stock (PFE) in November",
    "summary": "What would you say to a dividend yield of 7%?",
    "url": "https://www.fool.com/investing/2025/11/03/reason-buy-pfizer-stock-pfe-november/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "13e87112-67b5-3a76-9041-078d32a9e6b8",
      "content": {
        "id": "13e87112-67b5-3a76-9041-078d32a9e6b8",
        "contentType": "STORY",
        "title": "1 Incredible Reason to Buy Pfizer Stock (PFE) in November",
        "description": "",
        "summary": "What would you say to a dividend yield of 7%?",
        "pubDate": "2025-11-03T09:00:00Z",
        "displayTime": "2025-11-03T09:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/5273ee7b71caddc28b8bc319fb117e2b",
          "originalWidth": 1024,
          "originalHeight": 652,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nlR4OBXkE.JJlYvNvwy4IA--~B/aD02NTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/5273ee7b71caddc28b8bc319fb117e2b.cf.webp",
              "width": 1024,
              "height": 652,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/v3X3tmT33qv6DTvJLfieuw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/5273ee7b71caddc28b8bc319fb117e2b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/03/reason-buy-pfizer-stock-pfe-november/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-incredible-reason-buy-pfizer-090000918.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T08:00:00+00:00",
    "headline": "Tariffs, pricing, backroom deals — how pharma can navigate wildly shifting policies",
    "summary": "Gaming out new regulations and various potential outcomes will help keep companies on more solid footing.",
    "url": "https://www.pharmavoice.com/news/tariffs-pharma-pricing-trump-fda-prizer-astrazeneca/804419/",
    "source": "Pharma Voice",
    "provider": "yfinance",
    "raw": {
      "id": "c6e2f282-ef40-30a9-8cae-a0ea879c1fa3",
      "content": {
        "id": "c6e2f282-ef40-30a9-8cae-a0ea879c1fa3",
        "contentType": "STORY",
        "title": "Tariffs, pricing, backroom deals — how pharma can navigate wildly shifting policies",
        "description": "",
        "summary": "Gaming out new regulations and various potential outcomes will help keep companies on more solid footing.",
        "pubDate": "2025-11-03T08:00:00Z",
        "displayTime": "2025-11-03T08:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharma_voice_330/af052fd153553671dc728ae51aec6e31",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MRN1uBQD8rUTlqPl579MIw--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharma_voice_330/af052fd153553671dc728ae51aec6e31.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNC8JAC.RzNVSTkkl7iUtQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharma_voice_330/af052fd153553671dc728ae51aec6e31.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharma Voice",
          "url": "https://www.pharmavoice.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmavoice.com/news/tariffs-pharma-pricing-trump-fda-prizer-astrazeneca/804419/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tariffs-pricing-backroom-deals-pharma-080000890.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN.L"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T07:42:54+00:00",
    "headline": "McDonald’s Earnings, Tariff Update, Musk Pay Vote: What to Watch This Week",
    "summary": "Following President Trump's return from Asia, eyes are on whether an end to the government shutdown is in sight. Meanwhile, investors will dig into earnings from McDonald’s, Palantir and a host of other companies.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-03-2025/card/mcdonald-s-earnings-tariff-update-musk-pay-vote-what-to-watch-this-week-RoN8F6Yf2gkz32oBKwYH?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "df6487af-0d38-38f5-85c6-f622488c55fe",
      "content": {
        "id": "df6487af-0d38-38f5-85c6-f622488c55fe",
        "contentType": "STORY",
        "title": "McDonald’s Earnings, Tariff Update, Musk Pay Vote: What to Watch This Week",
        "description": "",
        "summary": "Following President Trump's return from Asia, eyes are on whether an end to the government shutdown is in sight. Meanwhile, investors will dig into earnings from McDonald’s, Palantir and a host of other companies.",
        "pubDate": "2025-11-03T07:42:54Z",
        "displayTime": "2025-11-03T07:42:54Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/df6487af-0d38-38f5-85c6-f622488c55fe/mcdonald%E2%80%99s-earnings-tariff.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/d7931448f55c4ad739fd04163eccadc3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4Aa7LUkSJqo2ocW8DI5hlA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/d7931448f55c4ad739fd04163eccadc3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vE9eONZGUXtdI6Wa0XF7QA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/d7931448f55c4ad739fd04163eccadc3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-03-2025/card/mcdonald-s-earnings-tariff-update-musk-pay-vote-what-to-watch-this-week-RoN8F6Yf2gkz32oBKwYH?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "MCD"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "SHOP"
            },
            {
              "symbol": "UBER"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "APO"
            },
            {
              "symbol": "MAR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T06:35:35+00:00",
    "headline": "Metsera (MTSR) Jumps 20% as Big Pharma Battle Heats Up Over Takeover",
    "summary": "We recently published 10 Stocks With Easy 20-40% Gains. Metsera Inc. (NASDAQ:MTSR) is one of the last week’s best-performing stocks. Metsera saw its share prices jump by 20 percent week-on-week as investors gobbled up shares amid a billion-dollar bidding war between two pharmaceutical giants racing to gain a larger foothold in the booming weight-loss industry. […]",
    "url": "https://finance.yahoo.com/news/metsera-mtsr-jumps-20-big-063535132.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "d1bfe982-2def-3733-a5bf-6f83bd1bd978",
      "content": {
        "id": "d1bfe982-2def-3733-a5bf-6f83bd1bd978",
        "contentType": "STORY",
        "title": "Metsera (MTSR) Jumps 20% as Big Pharma Battle Heats Up Over Takeover",
        "description": "",
        "summary": "We recently published 10 Stocks With Easy 20-40% Gains. Metsera Inc. (NASDAQ:MTSR) is one of the last week’s best-performing stocks. Metsera saw its share prices jump by 20 percent week-on-week as investors gobbled up shares amid a billion-dollar bidding war between two pharmaceutical giants racing to gain a larger foothold in the booming weight-loss industry. […]",
        "pubDate": "2025-11-03T06:35:35Z",
        "displayTime": "2025-11-03T06:35:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/b244a3e71482649eb57d40ddb262c909",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Metsera (MTSR) Jumps 20% as Big Pharma Battle Heats Up Over Takeover",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aXuO2GBiXiUNLl3dgSP2JQ--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/b244a3e71482649eb57d40ddb262c909.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WtsA4z1DWCmMdk3GnV1kYQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/b244a3e71482649eb57d40ddb262c909.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/metsera-mtsr-jumps-20-big-063535132.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/metsera-mtsr-jumps-20-big-063535132.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T04:34:26+00:00",
    "headline": "3 Stocks Under $50 We’re Skeptical Of",
    "summary": "Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.",
    "url": "https://finance.yahoo.com/news/3-stocks-under-50-skeptical-043426392.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "3cbe56cb-711d-341b-b571-1be8035faee7",
      "content": {
        "id": "3cbe56cb-711d-341b-b571-1be8035faee7",
        "contentType": "STORY",
        "title": "3 Stocks Under $50 We’re Skeptical Of",
        "description": "",
        "summary": "Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.",
        "pubDate": "2025-11-03T04:34:26Z",
        "displayTime": "2025-11-03T04:34:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/ad9a5e2f85d880e3e7b521395022f4d3",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "VTRS Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kZ5PSZg5aKFn_8IHve8fGQ--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/ad9a5e2f85d880e3e7b521395022f4d3.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4bPZw8EZ18ugKQPfipbnLw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/ad9a5e2f85d880e3e7b521395022f4d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-stocks-under-50-skeptical-043426392.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-stocks-under-50-skeptical-043426392.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            },
            {
              "symbol": "ASGN"
            },
            {
              "symbol": "FHB"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T03:02:39+00:00",
    "headline": "Pfizer (PFE) Q3 Earnings: What To Expect",
    "summary": "Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.",
    "url": "https://finance.yahoo.com/news/pfizer-pfe-q3-earnings-expect-030239269.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "5a315394-6d31-37ce-8041-b03290fdd5fc",
      "content": {
        "id": "5a315394-6d31-37ce-8041-b03290fdd5fc",
        "contentType": "STORY",
        "title": "Pfizer (PFE) Q3 Earnings: What To Expect",
        "description": "",
        "summary": "Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.",
        "pubDate": "2025-11-03T03:02:39Z",
        "displayTime": "2025-11-03T03:02:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "PFE Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o3tZoPUio75qXATbHoc_Hg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5rZqD7vIoFGnsFYAS_Ztw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-q3-earnings-expect-030239269.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pfe-q3-earnings-expect-030239269.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T14:34:33+00:00",
    "headline": "Kimberly-Clark to buy Tylenol maker Kenvue, Iren & Microsoft deal",
    "summary": "There are a number of stocks on the move on Monday, Nov. 3. Kimberly-Clark (KMB) announced it is buying Kenvue (KVUE) in a deal valued at $48.7 billion. Iren (IREN) shares are soaring after striking a $9.7 billion deal with Microsoft (MSFT). Pfizer (PFE) is suing to block Novo Nordisk's (NVO) bid for obesity startup Metsera (MTSR). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finance.yahoo.com/video/kimberly-clark-buy-tylenol-maker-143433123.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "3ddef0a3-2d94-34b7-a290-3a8ad41203cc",
      "content": {
        "id": "3ddef0a3-2d94-34b7-a290-3a8ad41203cc",
        "contentType": "VIDEO",
        "title": "Kimberly-Clark to buy Tylenol maker Kenvue, Iren & Microsoft deal",
        "description": "<p>There are a number of stocks on the move on Monday, Nov. 3. Kimberly-Clark (<a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/quote/KMB\">KMB</a>) announced it is buying Kenvue (<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/KVUE\">KVUE</a>) in a deal valued at $48.7 billion. Iren (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/IREN\">IREN</a>) shares are soaring after striking a $9.7 billion deal with Microsoft (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/MSFT\">MSFT</a>). Pfizer (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/PFE\">PFE</a>) is suing to block Novo Nordisk's (<a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/NVO\">NVO</a>) bid for obesity startup Metsera (<a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/quote/MTSR\">MTSR</a>).</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:8;pos:1\" href=\"https://finance.yahoo.com/videos/series/morning-brief/\">Morning Brief</a>.</p>",
        "summary": "There are a number of stocks on the move on Monday, Nov. 3. Kimberly-Clark (KMB) announced it is buying Kenvue (KVUE) in a deal valued at $48.7 billion. Iren (IREN) shares are soaring after striking a $9.7 billion deal with Microsoft (MSFT). Pfizer (PFE) is suing to block Novo Nordisk's (NVO) bid for obesity startup Metsera (MTSR). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
        "pubDate": "2025-11-03T14:34:33Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/1ccb3110-b8c2-11f0-9e7b-4f79b62c5984",
          "originalWidth": 5800,
          "originalHeight": 3259,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Dum7UXSFTU2RBlRLNos2cg--~B/aD0zMjU5O3c9NTgwMDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/1ccb3110-b8c2-11f0-9e7b-4f79b62c5984.cf.webp",
              "width": 5800,
              "height": 3259,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0ZoyIISgVz.MU5Obbc5lhg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/1ccb3110-b8c2-11f0-9e7b-4f79b62c5984.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/kimberly-clark-buy-tylenol-maker-143433123.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/kimberly-clark-buy-tylenol-maker-143433123.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KMB"
            },
            {
              "symbol": "IREN"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "KVUE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]